CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $17.83.

CVRX has been the subject of a number of recent analyst reports. Craig Hallum increased their price target on shares of CVRx from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Canaccord Genuity Group raised their target price on shares of CVRx from $22.00 to $23.00 and gave the stock a "buy" rating in a research note on Wednesday, February 5th. William Blair upgraded shares of CVRx from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 14th. Finally, Piper Sandler boosted their price objective on CVRx from $16.00 to $20.00 and gave the stock an "overweight" rating in a report on Wednesday, February 5th.

CVRx Trading Down 0.5 %

CVRX traded down $0.06 during midday trading on Friday, reaching $12.70. 132,078 shares of the company were exchanged, compared to its average volume of 286,048. The stock has a market capitalization of $330.66 million, a P/E ratio of -4.72 and a beta of 1.34. CVRx has a one year low of $6.40 and a one year high of $19.85. The stock's 50-day simple moving average is $14.39 and its 200 day simple moving average is $12.72. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.23 and a current ratio of 12.06.

Remove Ads

CVRx (NASDAQ:CVRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. As a group, analysts forecast that CVRx will post -1.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in shares of CVRx by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock worth $49,000 after buying an additional 1,186 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of CVRx by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company's stock valued at $385,000 after purchasing an additional 1,296 shares in the last quarter. Barclays PLC grew its position in shares of CVRx by 12.1% during the 4th quarter. Barclays PLC now owns 21,378 shares of the company's stock worth $270,000 after buying an additional 2,311 shares during the period. Wells Fargo & Company MN raised its holdings in shares of CVRx by 86.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,894 shares of the company's stock valued at $113,000 after purchasing an additional 4,115 shares during the period. Finally, Jane Street Group LLC raised its position in shares of CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock worth $168,000 after purchasing an additional 5,053 shares during the period. Institutional investors own 75.27% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.